This article has been updated



Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.


We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))− and EGFR−) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case–case comparison was performed using unconditional logistic regression.


Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.


Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.


Breast cancer can be classified into several molecular subtypes based on gene expression profiling analyses (Perou et al, 2000; Sorlie et al, 2001), which can be approximated with the use of key immunohistochemical (IHC) markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), and basal markers such as epidermal growth factor receptor (EGFR), cytokeratin 5 (CK5) or cytokeratin 5/6 (CK5/6). In general, well-known breast cancer hormonal and lifestyle risk factors, such as early age at menarche, late age at first birth, nulliparity, prolonged interval between menarche and age at first birth, and postmenopausal obesity showed stronger associations with ER-positive (luminal) subtypes (Yang et al, 2011; Anderson et al, 2014). In contrast, these factors showed either a lack of association or associations in the opposite direction for ER-negative (non-luminal) tumours. For example, parity and premenopausal obesity were protective for luminal cancers but associated with increased risk for non-luminal tumours, particularly triple-negative breast cancer (TNBC: ER−/PR−/HER2−; Millikan et al, 2008; Phipps et al, 2011). We have previously shown that risk factor associations differed most strikingly between luminal A (ER+ or PR+/HER2−) and core-basal phenotype (CBP: TNBC expressing (CK5 or CK5/6) or EGFR), suggesting that these two subtypes may develop from etiologically different pathways (Yang et al, 2011).

Experimental and clinical studies suggest more complex layers of heterogeneity within major breast cancer subtypes (Perou et al, 2000; Sotiriou et al, 2003; Colleoni et al, 2012; Ali et al, 2014). In particular, luminal cancers demonstrated substantial variability in molecular characteristics (Cancer Genome Atlas Network, 2012) and clinical behaviour, including responsiveness to endocrine treatment (Ciriello et al, 2013; Howell, 2013; Ignatiadis and Sotiriou, 2013). In line with this, in a recent large pooled analysis including >10 000 invasive breast cancer cases, Blows et al, 2010 showed that luminal A tumours expressing basal markers ((CK5 or CK5/6) or EGFR, luminal A basal-positive) had worse prognosis than luminal A tumours that were negative for basal markers (luminal A basal-negative). However, to our knowledge, there have been no reports on etiological heterogeneity within luminal A tumours so far.

To assess whether luminal A basal-positive tumours (ER+ or PR+/HER2−/basal markers+) represent a distinct disease entity from an etiologic perspective, we pooled individual data for 5040 luminal A breast cancer cases contributed by eight studies participating in the Breast Cancer Association Consortium (BCAC), with risk factor information and expression status for ER, PR, HER2, and basal markers. The goal of this study was to examine whether tumour characteristics and risk factors of luminal A basal-positive tumours are different from those of luminal A basal-negative tumours (ER+ or PR+/HER2−/basal markers−).

Materials and methods

Study participants

Among studies participating in the BCAC (Yang et al, 2011), eight studies that had IHC data on ER (and/or PR), HER2, and basal markers (CK5 (or CK5/6) and/or EGFR) as well as breast cancer risk factor information were eligible for inclusion. Study details are summarised in Supplementary Table 1. These include four population-based studies (Kuopio Breast Cancer Project (KBCP), Melbourne Collaborative Cohort Study (MCCS), Nurses’ Health Study (NHS), and NCI’s Polish Breast Cancer Study (PBCS)) and four hospital-based case-control studies or studies of mixed design (Helsinki Breast Cancer Study (HEBCS), Mayo Clinic Breast Cancer Study (MCBCS), Sheffield Breast Cancer Study (SBCS), and Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH)). As the goal of our analysis was to determine whether tumour characteristics and risk factors differed by basal marker status within luminal tumours, we restricted the analysis to 5040 luminal A cases (ER+ or PR+/HER2−) that were known to express or not to express basal markers (CK5 (or CK5/6) or EGFR) (Table 1). Study participants were recruited under protocols approved by the institutional review board at each institution and all subjects provided written informed consent.

Table 1: Description of participating studies and distribution of tumour subtypes by study

Tumour marker assessment and subtype classification

ER, PR, and HER2 status were primarily extracted from medical records. Accordingly, the source of tumour marker data and definition of positivity for each marker varied across studies (Supplementary Table 2). Among 5040 luminal A cases defined based on medical records for ER and PR, centralised quantitative scores for ER or PR status obtained through automated imaging analysis of tissue microarrays were available for 3702 participants (Supplementary Table 3). More than 99% of luminal A cases (n=3670/3072) had tumours with 1% cells and 97% (n=3592/3072) with 10% tumour cells stained positive for either ER or PR, respectively. Given the high concordance of clinical data and centralised measurements for ER and PR, we used clinical data for these markers in the main analyses because they were available for more cases. Data for CK5 (or CK5/6) and EGFR status were obtained from centralised visual scoring of tissue microarray slides by pathologists. Expression was determined to be positive if >10% tumour cells were stained. When the proportion of positive cells was missing, positivity was defined based on the intensity score (2 as positive).

The number of cases in each study by marker status is presented in Supplementary Table 4. In the current study, we focused on two subtypes within luminal A tumours: basal-negative (ER+ or PR+/HER2−/(CK5 (or CK5/6))−/EGFR−) and basal-positive (ER+ or PR+/HER2−/(CK5 (or CK5/6))+ or EGFR+).

Breast cancer risk factors

The collection of information on tumour characteristics and risk factors for BCAC studies has been previously described (Yang et al, 2011). Briefly, each study collected information on one or more of the following factors: family history of breast cancer in first-degree relatives, age at menarche, age at menopause, age at first full-term pregnancy, parity (never/ever), number of children, breast feeding (never/ever), and body mass index (BMI) at baseline (MCCS and KBCP) or at the time of diagnosis (all others). NHS was not included in risk factor analysis owing to the lack of data.

Statistical analyses

We compared the distribution of tumour characteristics and risk factors between luminal A basal-negative and basal-positive subtypes using unconditional logistic regression with luminal A basal-negative subtype as the reference group. Tumour characteristics included histology (ductal, lobular, other), grade (well, moderately, poorly differentiated), size (2 cm, >2 cm), and axillary node status (negative, positive). Breast cancer risk factors included family history of breast cancer among first-degree relatives (present, absent), age at menarche (12, 13–14, >14 years), parity (parous, nulliparous), and BMI (<25, 25–30, 30 kg m−2 or per 5 unit of increase); and in analyses restricted to parous women included age at first full-term birth (<20, 20–24, 25–29, 30 years), number of full-term pregnancies (1, 2, 3), and breast feeding (ever, never). Multivariable models were used in all analyses to control for age (10-year frequency), study, other tumour characteristics and risk factors. Given that risk associated with BMI is known to vary by menopausal status, we stratified the BMI analysis by menopausal status. We used age groups (<50 and 50 years) as a surrogate for menopausal status to maximise power. A sensitivity analysis using known menopausal status yielded similar results. Between-study heterogeneity was assessed with I2 statistics using study-specific odds ratio (ORs) and 95% confidence intervals (CIs). Analyses were conducted using SAS (version 9.3; SAS Institute, Cary, NC, USA) or Stata/SE (version 11.2; StataCorp LP, College Station, TX, USA).


Among all 7857 invasive breast cancer cases in the 8 studies, 63.3% (n=4490) and 7.8% (n=550) were classified as luminal A basal-negative and luminal A basal-positive subtype, respectively (Table 1). Mean age at diagnosis was not significantly different between the two subtypes, although women with luminal A basal-positive tumours were diagnosed less frequently after 60 years compared with the women with luminal A basal-negative tumours (Table 2). Compared with the luminal A basal-negative tumours, basal-positive tumours were more likely to be smaller (OR>2 cm vs 2 cm=0.83; 95% CI=0.67–1.03; P=0.09; I2=0%) and negative for axillary nodes (OR=0.83; 95% CI=0.67–1.02; P=0.08; I2=0%), however, the differences were not statistically significant. The association with tumour grade did not follow a logical trend, with luminal A basal-positive tumours showing a lower frequency of moderately differentiated tumours (OR=0.75; 95% CI=0.60–0.94; P=0.01), but a higher frequency of poorly differentiated tumours (OR=1.13; 95% CI=0.85–1.50; P=0.42) compared with luminal A basal-negative tumours (Table 2). Study heterogeneity was not significant in the former (I2=10.2%; P=0.35) but was significant in the latter association (I2=63.2%; P=0.01).

Table 2: Comparison of tumour characteristics between luminal A basal-negative and basal-positive subtypes

Compared with basal-negative cases, cases with luminal A basal-positive tumours were more likely to have a positive family history (OR=1.27; 95% CI=0.99–1.63; P=0.06; I2=1.1%; Table 3) particularly among younger (<50 years) women (OR=1.81; 95% CI=1.16–2.82; P=0.009). In addition, basal-positive cases tended to have lower BMI (ORper 5 unit=0.90; 95% CI=0.81–1.01, P=0.07; I2=0.0%) especially among older (50 years) women (ORper 5 unit=0.89; 95% CI=0.79–1.01, P=0.07; I2=15.5%) compared with basal-negative cases, but the differences were weak and the test of interaction by age group did not reach nominal significance (P<0.05). Other risk factors did not differ significantly between the two subtypes.

Table 3: Comparison of risk factors between luminal A basal-negative and basal-positive subtypes

To reduce the impact of potential subtype misclassification, we conducted a sensitivity analysis by restricting our analyses to cases showing ER expression in 10% and PR expression in 20% tumour cells. Among 3015 basal-negative and 366 basal-positive cases with ER and PR percentage data available, 2372 (79%) basal-negative and 299 (82%) basal-positive cases were included in the sensitivity analysis. The only difference we observed was that luminal A basal-positive tumours now had a similar, rather than a higher, proportion of poorly differentiated tumours to luminal A basal-negative tumours. ORs for other tumour characteristics and risk factors did not change substantially (Supplementary Table 5).


In a previous BCAC analysis (Blows et al, 2010), we showed that all-cause mortality among cases with luminal A basal-positive tumours was slightly but significantly higher than that of cases with luminal A basal-negative tumours, and the difference was persistent up to 15 years after diagnosis. Similar but non-significant difference in survival by basal marker expression (adjusted hazard ratio=1.20basal-positive vs basal-negative; 95% CI=0.69–2.08, P=0.51) was observed in our study when we analysed a subset of cases (1245 luminal A cases; 1124 basal-negative cases, and 121 basal-positive cases) with the follow-up data available. Interestingly, luminal A basal-positive tumours were not associated with more aggressive features, rather, they tended to be less aggressive (smaller, lower grade, and node negative) compared with basal-negative tumours.

The apparent discrepancy between less aggressive tumour features and poorer prognosis in basal-positive cases might be explained by different responses to endocrine therapy among cases with luminal tumours. Previous studies using luminal tumour xenografts identified a subpopulation of ER-PR-CK5+ cells that were resistant to endocrine therapies (Horwitz et al, 2008); when ER+ tumours with ER-PR-CK5+ cells were treated with 17β-estradiol plus anti-estrogens tamoxifen or fulvestrant, the number of CK5+ cells in post compared with pre-treatment tumours coupled with decreased expression of ER and increased expression of CK5 (Kabos et al, 2011). Studies with detailed pathology data incorporating cellular subpopulation, as well as treatment regimens with long-term follow-up are needed to definitively address this question.

Known breast cancer risk factors did not appear to vary significantly by basal marker expression within luminal A tumours, although we observed weak associations between basal-positive tumours and higher frequency of positive family history especially among younger women and lower prevalence of obesity. The higher frequency of slim women with luminal A basal-positive tumours might be also related to smaller tumour size of luminal A basal-positive tumours as we observed a significant correlation between tumour size and BMI among our study subjects. Indeed, when we adjusted for BMI, the association between luminal A basal-positive subtype and smaller tumour size was attenuated (OR=0.87; 95% CI=0.69–1.09; P=0.22). This finding is consistent with previous reports that obese breast cancer patients had larger tumours and higher rates of lymph node metastases (Ewertz et al, 2011; Haakinson et al, 2012).

Our study has limitations. Although it is one of the largest consortium studies with breast tumour subtype information and risk factor data collected, statistical power was limited to assess risk factors in uncommon subtypes especially when controlling for potential confounding factors such as breastfeeding, menopausal hormone therapy usage, and tumour size. As expected for any analysis pooling data from multiple studies, there were variations in study populations, study designs, data collection methods, and marker measurement, which may cause study heterogeneity and subtype misclassification. However, we found no significant heterogeneity across studies at least for the associations in risk factors we analysed. In addition, the proportions of CBP (8.5%) and 5-NP (6.3%) subtypes were also comparable to those reported previously (Cheang et al, 2008; Blows et al, 2010; Yang et al, 2011; Liu et al, 2012). Of note, although we used centralised measurement for CK5/6 and EGFR expression, we used ER, PR, and HER2 status retrieved from clinical records in each study instead of centralised data to maximise the power of our study. Accordingly, IHC methods and cut-point for positivity varied substantially among studies. However, we observed high concordance for ER and PR status between clinical records and centralised quantitative measurements among a subset of study subjects with both data available. Further, the overall proportions of positivity for these five markers (ER, 78.0%; PR, 64.2%; HER2, 14.5%; CK5/6, 13.5%; EGFR, 12.8%) were generally consistent with what was reported in previous studies (El-Rehim et al, 2004; Carey et al, 2006; Rakha et al, 2006; Cheang et al, 2008; Liu et al, 2012). Finally, information on proliferation marker (such as Ki-67) was not available for most studies, which made the accurate classification of real luminal A tumours a challenge. However, results from the sensitivity analysis restricting to cases with high ER and PR expression levels using centralised data did not change results significantly, suggesting that the potential subtype misclassification caused by study heterogeneity or marker measurement and scoring did not significantly influence our conclusion.

In conclusion, we found that tumour characteristics and known risk factors were generally similar in basal-positive and basal-negative luminal A tumours. The small differences in tumour features and family history between the two luminal A subtypes warrant further investigations in future studies with larger number of subjects and detailed annotation of subtype and risk factor information.

Change history

  • 02 February 2016


  1. , , , , , , (2014) Genome-driven integrated classification of breast cancer validated in over 7500 samples. Genome Biol 15: 431.

  2. , , (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144: 1–10.

  3. , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10 159 cases from 12 studies. Plos Med 7: e1000279.

  4. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.

  5. , , , , , , , , , , , , , , , , (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492–2502.

  6. , , , , , , , (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368–1376.

  7. , , , , , , , (2013) The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat 141: 409–420.

  8. , , , , , , , , , , , , , , , (2012) Outcome of special types of luminal breast cancer. Ann Oncol 23: 1428–1436.

  9. , , , , , , , (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661–671.

  10. , , , , , , , , (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29: 25–31.

  11. , , , , , , , , (2012) The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol 19: 3012–3018.

  12. , , , , (2008) Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 105: 5774–5779.

  13. (2013) Advances in the treatment of luminal breast cancer. Curr Opin Obstet Gynecol 25: 49–54.

  14. , (2013) Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 10: 494–506.

  15. , , , , , , , (2011) Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 128: 45–55.

  16. , , , , , (2012) CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14(2): R48.

  17. , , , , , , , , , , , , , , , (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109: 123–139.

  18. , , , , , , , , , , , , , , , , , (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.

  19. , , , , , , , , , , , , (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103: 470–477.

  20. , , , , , , , , (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42: 3149–3156.

  21. , , , , , , , , , , , , , , , , (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874.

  22. , , , , , , , , , (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393–10398.

  23. , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103: 250–263.

Download references


The Helsinki Breast Cancer Study (HEBCS) thanks Kristiina Aittomäki, Kirsimari Aaltonen, Taru A Muranen, Karl von Smitten, and Irja Erkkilä for their kind help with the patient samples and data. The Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH) thanks Elena Provenzano and Marie Mack. The HEBCS was supported by The Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and The Nordic Cancer Union and the Sigrid Juselius Foundation. The Mayo Clinic Breast Cancer Study (MCBCS) was supported by The Breast Cancer Research Foundation, the National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), R01 grants (CA128978 and CA176785), and the Grohne Family. The Melbourne Collaborative Cohort Study (MCCS) was supported by The Cancer Council Victoria, VicHealth, NHMRC (209057, 251533, 396414, and 504711), Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index (NDI). The Nurses’ Health Study (NHS) was supported by National Institutes of Health/National Cancer Institute (UM1 CA186107 and P01 CA 87969). The NHS thanks the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The Polish Breast Cancer Study (PBCS) was supported by Intramural Research Program of US NIH, NCI, Division of Cancer Epidemiology and Genetics (DCEG). The Sheffield Breast Cancer Study (SBCS) was supported by Yorkshire Cancer Research (S295, S299, and S305PA) and Sheffield Experimental Cancer Medicine Centre. The SEARCH was supported by Cancer Research UK (C490/A16561), the Biomedical Research Centre at the University of Cambridge. The Kuopio Breast Cancer Project (KBCP) was supported by The special Government Funding of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the strategic funding of the University of Eastern Finland.

Author information


  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Bethesda, 20850 MD, USA

    • Hyuna Sung
    • , Jonine Figueroa
    • , Mark E Sherman
    •  & Xiaohong R Yang
  2. Division of Breast Cancer Research, Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey, SM2 5NG London, UK

    • Montserrat Garcia-Closas
  3. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

    • Jenny Chang-Claude
  4. Department of Oncology, University of Cambridge, Worts Causeway, CB1 8RN Cambridge, UK

    • Fiona M Blows
  5. Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, CB2 0RE Cambridge, UK

    • H Raza Ali
  6. Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, PO Box 700, 00029 HUS Helsinki, Finland

    • Heli Nevanlinna
    •  & Rainer Fagerholm
  7. Department of Pathology, Helsinki University Hospital and University of Helsinki, PO Box 400, 00029 Helsinki, Finland

    • Päivi Heikkilä
  8. Department of Oncology, Helsinki University Hospital and University of Helsinki, PO Box 400, 00029 Helsinki, Finland

    • Carl Blomqvist
  9. Cancer Epidemiology Centre, Cancer Council Victoria, 615 St Kilda Rd, Melbourne, 3004 Victoria, Australia

    • Graham G Giles
    •  & Roger L Milne
  10. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, 3010 Victoria, Australia

    • Graham G Giles
    •  & Roger L Milne
  11. Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, 3010 Victoria, Australia

    • Melissa C Southey
  12. Anatomical Pathology, The Alfred Hospital, Commercial Rd, Prahran, 3181, 3053 Victoria, Australia

    • Catriona McLean
  13. School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Cancer Center of Eastern Finland, University of Eastern Finland, Yliopistonranta 1, PO Box 1627, 70211 Kuopio, Finland

    • Arto Mannermaa
    • , Veli-Matti Kosma
    •  & Reijo Sironen
  14. Department of Clinical Pathology, Imaging Center, Kuopio University Hospital, PO Box 100, 70029 KYS Kuopio, Finland

    • Arto Mannermaa
    • , Veli-Matti Kosma
    •  & Reijo Sironen
  15. Jyväskylä Central Hospital, Central Finland Health Care District, Adm Bldg 6/2, Keskussairaalantie 19, 40620 Jyväskylä, Finland

    • Vesa Kataja
  16. Department of Laboratory Medicine and Pathology, Mayo Clinic, Stabile 2-42, 200 First Street SW, Rochester, 55905 MN, USA

    • Fergus J Couch
  17. Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, 55905 MN, USA

    • Janet E Olson
    • , Emily Hallberg
    •  & Curtis Olswold
  18. Sheffield Cancer Research, Department of Oncology, University of Sheffield, Beech Hill Road, S10 2RX Sheffield, UK

    • Angela Cox
  19. Department of Neuroscience, University of Sheffield, Beech Hill Road, S10 2RX Sheffield, UK

    • Simon S Cross
  20. Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, 02115 MA, USA

    • Peter Kraft
  21. Department of Medicine, Channing Division of Network Medicine, Harvard Medical School and Brigham and Women’s Hospital, 181 Longwood Avenue, Boston, 02115 MA, USA

    • Rulla M Tamimi
    •  & A Heather Eliassen
  22. Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, 02115 MA, USA

    • Rulla M Tamimi
    •  & A Heather Eliassen
  23. Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

    • Marjanka K Schmidt
  24. Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, CB1 8RN Cambridge, UK

    • Manjeet K Bolla
    • , Qin Wang
    • , Douglas Easton
    •  & Paul DP Pharoah
  25. Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, CB1 8RN Cambridge, UK

    • Douglas Easton
    •  & Paul DP Pharoah
  26. Cancer Research UK Cambridge Institute, Li Ka Shing Centre, CB2 0RE Cambridge, UK

    • William J Howat
  27. Division of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey, SM2 5NG London, UK

    • Penny Coulson


  1. Search for Hyuna Sung in:

  2. Search for Montserrat Garcia-Closas in:

  3. Search for Jenny Chang-Claude in:

  4. Search for Fiona M Blows in:

  5. Search for H Raza Ali in:

  6. Search for Jonine Figueroa in:

  7. Search for Heli Nevanlinna in:

  8. Search for Rainer Fagerholm in:

  9. Search for Päivi Heikkilä in:

  10. Search for Carl Blomqvist in:

  11. Search for Graham G Giles in:

  12. Search for Roger L Milne in:

  13. Search for Melissa C Southey in:

  14. Search for Catriona McLean in:

  15. Search for Arto Mannermaa in:

  16. Search for Veli-Matti Kosma in:

  17. Search for Vesa Kataja in:

  18. Search for Reijo Sironen in:

  19. Search for Fergus J Couch in:

  20. Search for Janet E Olson in:

  21. Search for Emily Hallberg in:

  22. Search for Curtis Olswold in:

  23. Search for Angela Cox in:

  24. Search for Simon S Cross in:

  25. Search for Peter Kraft in:

  26. Search for Rulla M Tamimi in:

  27. Search for A Heather Eliassen in:

  28. Search for Marjanka K Schmidt in:

  29. Search for Manjeet K Bolla in:

  30. Search for Qin Wang in:

  31. Search for Douglas Easton in:

  32. Search for William J Howat in:

  33. Search for Penny Coulson in:

  34. Search for Paul DP Pharoah in:

  35. Search for Mark E Sherman in:

  36. Search for Xiaohong R Yang in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to Hyuna Sung.

Supplementary information

About this article

Publication history






This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (

Further reading